Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Grants GenMark License to Microfluidics Patent Portfolio

NEW YORK (GenomeWeb News) – GenMark Diagnostics today said it has been granted a non-exclusive license to PerkinElmer's microfluidics patent portfolio.

Financial and other terms of the deal were not disclosed.

GenMark President and CEO Hany Massarany said in a statement, "Completing this agreement strengthens GenMark's patent portfolio and provides us with maximum flexibility as we expand our menu of high-value multiplex molecular tests."

PerkinElmer fortified its microfluidics portfolio with the $600 million acquisition of Caliper Life Sciences in November.

"The use of microfluidics for multiplexed molecular testing is a key enabling platform for personalized health research," Kevin Hrusovsky, president of Life Sciences and Technology for PerkinElmer, said. "We continue to leverage our expansive microfluidics portfolio, through non-exclusive licensing such as the one with GenMark, to extend our market reach and create revenue opportunities in applications and markets that complement our direct channel product offerings."

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.